{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT03627767_JADE_MONO2\\NCT03627767_JADE_MONO2_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Full Analysis Set - Open Label",
        "text": "This is the set of all subjects who received at least one dose of study treatment during the open label run-in phase.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS-OL",
        "populationDescription": "This is the set of all subjects who received at least one dose of study treatment during the open label run-in phase.",
        "criteria": "Received >=1 dose of study treatment during the open label run-in phase"
      },
      {
        "id": "pop_2",
        "name": "Full Analysis Set - Randomized",
        "text": "This is the set of all subjects who have been randomized at Week 12 and have received at least one dose of study treatment within the double-blind phase. By study design, this will be a subset of FAS-OL. Subjects are assigned to the randomized treatment group regardless of actual treatment received.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS-RA",
        "populationDescription": "This is the set of all subjects who have been randomized at Week 12 and have received at least one dose of study treatment within the double-blind phase. By study design, this will be a subset of FAS-OL. Subjects are assigned to the randomized treatment group regardless of actual treatment received.",
        "criteria": "Randomized at Week 12 AND received >=1 dose of study treatment within the double-blind phase"
      },
      {
        "id": "pop_3",
        "name": "Per Protocol Analysis Set",
        "text": "The Per Protocol Analysis Set (PPAS) is not fully defined in the provided text snippet (Section 4.2 header exists but text is cut off), however, it typically includes subjects from the FAS who completed the study without major protocol deviations.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PPAS",
        "populationDescription": "The Per Protocol Analysis Set (PPAS) is not fully defined in the provided text snippet (Section 4.2 header exists but text is cut off), however, it typically includes subjects from the FAS who completed the study without major protocol deviations.",
        "criteria": "FAS members without major protocol deviations"
      },
      {
        "id": "pop_4",
        "name": "Safety Analysis Set",
        "text": "Safety will be assessed... in all subjects who receive at least one dose of the investigational product. (Note: Section 4.3 header exists but full text is cut off; definition is derived from Section 3.5).",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "Safety will be assessed... in all subjects who receive at least one dose of the investigational product. (Note: Section 4.3 header exists but full text is cut off; definition is derived from Section 3.5).",
        "criteria": "Received >=1 dose of investigational product"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Age category (<18 years and >=18 years) used as a stratification factor."
      },
      {
        "id": "char_2",
        "name": "Body Weight",
        "code": "BODY_WEIGHT",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Body Weight",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Weight in kg; inclusion criteria requires >=40 kg."
      },
      {
        "id": "char_3",
        "name": "EASI Score",
        "code": "EASI_SCORE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "EASI Score",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Eczema Area and Severity Index score used to define response and flare."
      },
      {
        "id": "char_4",
        "name": "IGA Score",
        "code": "IGA_SCORE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "IGA Score",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Investigatorâ€™s Global Assessment score (5-point scale)."
      }
    ],
    "summary": {
      "populationCount": 4,
      "characteristicCount": 4
    }
  }
}